Health Technology Assessment Report: HPV Vaccine in Healthcare

This report provides a comprehensive health technology assessment of the Human Papillomavirus (HPV) vaccine, examining its efficacy, safety, and cost-effectiveness. The assessment begins with an abstract summarizing the key findings of the study, including the significant reduction in HPV infection among vaccinated women compared to the placebo group. It delves into the clinical evidence supporting the vaccine's effectiveness, including the results of a randomized double-blind placebo-controlled trial. The report also includes an economic evaluation of the vaccine's cost-effectiveness, comparing the cost per life-year and quality-adjusted life-year gained when incorporating the HPV vaccine into the national cervical cancer screening program. The evaluation considers the resources used, sources of uncertainty, and assumptions made during the economic analysis. The report assesses the applicability of the HPV vaccine in the Australian context, considering its potential impact on the health budget. The report concludes with a recommendation that the HPV vaccine should be funded, based on the evidence of cost reduction due to the decreased need for cervical cancer treatment.